WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.

MLA

Bosch, Linda J. W., et al. “WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 22, no. 18, Sept. 2016, pp. 4612–22. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-15-2703.

APA

Bosch, L. J. W., Luo, Y., Lao, V. V., Snaebjornsson, P., Trooskens, G., Vlassenbroeck, I., Mongera, S., Tang, W., Welcsh, P., Herman, J. G., Koopman, M., Nagtegaal, I. D., Punt, C. J. A., van Criekinge, W., Meijer, G. A., Monnat, R. J., Jr, Carvalho, B., & Grady, W. M. (2016). WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(18), 4612–4622. https://doi.org/10.1158/1078-0432.CCR-15-2703

Chicago

Bosch, Linda J W, Yanxin Luo, Victoria V Lao, Petur Snaebjornsson, Geert Trooskens, Ilse Vlassenbroeck, Sandra Mongera, et al. 2016. “WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 22 (18): 4612–22. doi:10.1158/1078-0432.CCR-15-2703.